FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:307-309 January 19, 2006 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Rosalyn Yalow, the inventor of radioimmunoassay, found that insulin treatments led to the production of antibodies against insulin.¹ Initially, this phenomenon was thought to be due to slight immunogenicity induced by the refining of preparations or the difference in amino acid sequences between species. However, even today, when genetically engineered preparations of human insulin are used, anti–human insulin IgG subclasses still are frequently detected in patients treated with insulin. Why therapeutically used insulin molecules, despite having exactly the same primary structure as endogenous insulin, are immunogenic has not been fully clarified.

We describe the induction of immunologic . . . [Full Text of this Article]

This article has been cited by other articles:

• Noronha, A. (2007). Neutralizing antibodies to interferon. Neurology 68: S16-S22 [Abstract] [Full Text]